NDA 216951 · Glaxosmithkline
Jesduvroq
Daprodustat · Oral · Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor
NovelDiscontinuedCDER novel approval, Feb 1, 2023: To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months
Last checked: Nov 19, 2026Latest source record: Feb 1, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Feb 1, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
38
10 Phase 3, 0 recruiting
FAERS reports
1,993
1,889 serious, 439 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS JESDUVROQ increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) [see Warnings and Precautions ( 5.1 )] . Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels [see Warnings and Precautions ( 5.1 )] . No trial has identified a hemoglobin target level, dose of JESDUVROQ, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.4 )]. Use the lowest dose of JESDUVROQ sufficient to reduce the need for red blood cell transfusions [see Dosage and Administration ( 2.4 )] . WARNING: INCREASED RISK OF DEATH,...
What it is approved for
From the label in effect Aug 30, 2023.
JESDUVROQ is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. Limitations of Use JESDUVROQ has not been shown to improve quality of life, fatigue, or patient well-being. JESDUVROQ is not indicated for use: • As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. • For treatment of anemia of chronic kidney disease in patients who are not on dialysis. JESDUVROQ is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months. ( 1 ) Limitations of Use Not shown to improve quality of life, fatigue, or patient well-being. Not indicated for use: • As a substitute for transfusion in patients requiring immediate correction of anemia. • In patients not on dialysis.
Mechanism: Daprodustat is a reversible inhibitor of HIF-PH1, PH2 and PH3 (IC 50 in the low nM range). This activity results in the stabilization and nuclear accumulation of HIF-1α and HIF-2α transcription factors, leading to increased transcription of the HIF-responsive genes, including erythropoietin.
Therapeutic areas: Hematology and blood cancers · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 1, 2023 Original approval · Type 1 - New Molecular Entity NovelLetterLabelMedication Guide
5 products under this application
- JESDUVROQ · DAPRODUSTAT 6MG · TABLET, ORAL · Discontinued
- JESDUVROQ · DAPRODUSTAT 2MG · TABLET, ORAL · Discontinued
- JESDUVROQ · DAPRODUSTAT 8MG · TABLET, ORAL · Discontinued
- JESDUVROQ · DAPRODUSTAT 4MG · TABLET, ORAL · Discontinued
- JESDUVROQ · DAPRODUSTAT 1MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Daprodustat" as an intervention, any sponsor and status, largest first.
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02876835 · 3,872 participants · Start Sep 27, 2016 · Primary completion Apr 19, 2021
Drug: Daprodustat; Darbepoetin alfa and 2 more · For: Anaemia
Sites: Andalusia, Alabama; Birmingham, Alabama; Huntsville, Alabama · 574 sites in all
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02879305 · 2,964 participants · Start Sep 28, 2016 · Primary completion Nov 9, 2020
Drug: Daprodustat; rhEPO and 2 more · For: Anaemia; Aspergillosis, Allergic Bronchopulmonary
Sites: Huntsville, Alabama; Pine Bluff, Arkansas; Anaheim, California · 462 sites in all
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT03409107 · 614 participants · Start Mar 5, 2018 · Primary completion Oct 7, 2020
Drug: Daprodustat (GSK1278863); Placebo and 1 more · For: Anaemia
Sites: Homewood, Alabama; Little Rock, Arkansas; Downey, California · 168 sites in all
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT03400033 · 407 participants · Start Sep 5, 2018 · Primary completion Jun 19, 2020
Drug: Daprodustat tablets; Matching placebo tablets and 2 more · For: Anaemia
Sites: Mesa, Arizona; Fresno, California; Los Angeles, California · 91 sites in all
- Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal AnemiaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02791763 · 355 participants · Start Jun 6, 2016 · Primary completion Oct 26, 2018
Drug: 1 to 4 mg tablets of GSK1278863; 6 mg GSK1278863 tablet and 1 more · For: Anaemia
Sites: Aichi, Japan; Chiba, Japan; Ehime, Japan · 56 sites in all
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT03029208 · 312 participants · Start May 11, 2017 · Primary completion Sep 24, 2020
Drug: Daprodustat; Darbepoetin alfa and 1 more · For: Anaemia
Sites: Anaheim, California; Cerritos, California; Escondido, California · 111 sites in all
- A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02969655 · 271 participants · Start Nov 21, 2016 · Primary completion Jul 2, 2018
Drug: Daprodustat small; Daprodustat small placebo and 4 more · For: Anaemia
Sites: Aichi, Japan; Chiba, Japan; Ehime, Japan · 50 sites in all
- Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy ParticipantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04640311 · 259 participants · Start Dec 18, 2020 · Primary completion May 18, 2021
Drug: Daprodustat · For: Anaemia
Sites: Anaheim, California; Overland Park, Kansas; Las Vegas, Nevada · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hospitalisation299
- off label use166
- product use issue160
- death118
- haemoglobin decreased102
- renal impairment97
- cardiac failure94
- haemoglobin increased85
- dysphagia83
- nephrogenic anaemia73
- marasmus64
- cerebral infarction59
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 2 |
| 2018 | 23 |
| 2019 | 20 |
| 2020 | 12 |
| 2021 | 53 |
| 2022 | 47 |
| 2023 | 550 |
| 2024 | 487 |
| 2025 | 489 |
| 2026 | 310 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Jesduvroq (Daprodustat)
2024 spending
$23K
Beneficiaries
11
38 claims
Per beneficiary
$2,050
$18.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $22,551 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Singh AK, Carroll K, Perkovic V, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
Singh AK, Carroll K, McMurray JJV, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia.
Mahar KM, Yang S, Mesic E, et al. · Clin Pharmacokinet 2024 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.
Dasgupta I, Meadowcroft AM, Bhatt PR, et al. · Nephrol Dial Transplant 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients.
Kanai H, Nangaku M, Nagai R, et al. · Ther Apher Dial 2021 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of daprodustat versus darbepoetin alfa in the treatment of anemia in chronic renal failure: Systematic review and meta-analysis of randomized controlled trials.
Pang S, Wang Z, Fu Y, et al. · J Pharmacol Sci 2025 · Meta-Analysis, Systematic Review
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.